TGFBI作为早期子宫内膜异位症无创诊断的候选生物标志物
本研究为病例对照研究,分发现期(56例)和验证期(237例),评估COMP和TGFBI单独或联合CA-125作为子宫内膜异位症血液生物标志物的价值。发现期显示子宫内膜异位症患者血浆TGFBI浓度显著升高而COMP无诊断价值;验证期TGFBI联合CA-125的SVM模型与单独CA-125对全部期内异症诊断特征相似,TGFBI对早期(rASRM I-II期)诊断潜力较好(AUC 0.74)。
要点
- COMP对子宫内膜异位症无诊断价值
- TGFBI对早期子宫内膜异位症有较好诊断潜力(AUC 0.74)
- TGFBI联合CA-125对中重度内异症AUC达0.94、灵敏度95%
核心结论
- COMP无诊断价值;TGFBI是早期子宫内膜异位症的潜在无创生物标志物;TGFBI联合CA-125对全部期内异症的诊断特征与单独CA-125相似。
研究设计与样本
- 病例对照研究,分发现期(n=56)和验证期(n=237),患者于2008年至2019年在一家三级医疗中心接受治疗。
- 发现期包括32例子宫内膜异位症患者和24例确诊无子宫内膜异位症的对照;验证期包括166例内异症和71例对照。
- 血浆COMP和TGFBI用ELISA检测,血清CA-125用临床验证过的检测方法测定,采用线性支持向量机(SVM)构建分类模型。
主要发现
- 发现期子宫内膜异位症患者血浆TGFBI浓度较对照显著升高,COMP无显著差异。
- 发现期TGFBI单变量ROC分析AUC 0.77、灵敏度58%、特异度84%;TGFBI联合CA-125的SVM模型AUC 0.91、灵敏度88%、特异度75%。
- 验证期TGFBI联合CA-125的SVM模型AUC 0.83、灵敏度83%、特异度67%;单独CA-125 AUC 0.83、灵敏度73%、特异度80%。
- TGFBI对早期(修订美国生殖医学学会I-II期)子宫内膜异位症AUC 0.74、灵敏度61%、特异度83%;CA-125 AUC 0.63、灵敏度60%、特异度67%。
- TGFBI联合CA-125的SVM模型对中重度子宫内膜异位症诊断AUC 0.94、灵敏度95%。
局限性
- 诊断模型在单一子宫内膜异位症中心建立和验证,需在多中心、更大队列研究中进一步验证和技术确认。
- 验证期部分患者缺乏组织学确诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can cartilage oligomeric matrix protein (COMP) and transforming growth factor-β-induced protein ig-h3 (TGFBI) alone or in combination with cancer antigen 125 (CA-125) be considered as potential blood biomarkers of endometriosis? SUMMARY ANSWER: The results of this study indicate that COMP has no diagnostic value. TGFBI has potential as a non-invasive biomarker of the early stages of endometriosis, while TGFBI together with CA-125 has similar diagnostic characteristics as CA-125 alone for all stages of endometriosis. WHAT IS KNOWN ALREADY: Endometriosis is a common, chronic gynecological disease that significantly affects patient quality of life by causing pain and infertility. The gold standard for diagnosis is visual inspection of pelvic organs by laparoscopy, therefore there is an urgent need for discovery of non-invasive biomarkers for endometriosis to reduce diagnostic delays and allow earlier treatment of patients. The potential biomarkers for endometriosis evaluated in this study (COMP and TGFBI) were previously identified by our proteomic analysis of peritoneal fluid samples. STUDY DESIGN, SIZE, DURATION: This is a case-control study divided into a discovery (n = 56 patients) and a validation phase (n = 237 patients). All patients were treated between 2008 and 2019 in a tertiary medical center. PARTICIPANTS/MATERIALS, SETTING, METHOD: Patients were stratified based on the laparoscopic findings. The discovery phase included 32 endometriosis patients (cases) and 24 patients with confirmed absence of endometriosis (controls). The validation phase included 166 endometriosis and 71 control patients. Concentrations of COMP and TGFBI were measured by ELISA in plasma samples, whereas concentration of CA-125 was measured using a clinically validated assay for serum samples. Statistical and receiver operating characteristic (ROC) curve analyses were performed. The classification models were built using the linear support vector machine (SVM) method with the SVM built-in feature ranking method. MAIN RESULTS AND THE ROLE OF CHANCE: The discovery phase revealed significantly increased concentration of TGFBI, but not COMP, in plasma samples of patients with endometriosis compared to controls. In this smaller cohort, univariate ROC analysis showed fair diagnostic potential of TGFBI, with an AUC value of 0.77, sensitivity of 58%, and specificity of 84%. The classification model built using linear SVM and combining TGFBI and CA-125 showed an AUC value of 0.91, sensitivity of 88% and specificity of 75% in distinguishing patients with endometriosis from controls. The validation phase results revealed similar diagnostic characteristics of the SVM model combining TGFBI and CA-125, with an AUC value of 0.83, sensitivity of 83% and specificity of 67% and CA-125 alone with AUC value of 0.83, sensitivity of 73% and specificity of 80%. TGFBI exhibited good diagnostic potential for early-stage endometriosis (revised American Society for Reproductive Medicine stage I-II), with an AUC value of 0.74, sensitivity of 61% and specificity of 83% compared to CA-125, which had an AUC value of 0.63, sensitivity of 60% and specificity of 67%. An SVM model combining TGFBI and CA-125 showed a high AUC value of 0.94 and sensitivity of 95% for diagnosing moderate-to-severe endometriosis. LIMITATIONS, REASONS FOR CAUTION: The diagnostic models were built and validated from a single endometriosis center, and thus further validation and technical verification in a multicenter study with a larger cohort is needed. Additional limitation was lack of histological confirmation of disease for some patients in the validation phase. WIDER IMPLICATIONS OF THE FINDINGS: This study revealed for the first time increased concentration of TGFBI in plasma samples of patients with endometriosis, particularly those with minimal-to-mild endometriosis, compared to controls. This is the first step in considering TGFBI as a potential non-invasive biomarker for the early stages of endometriosis. It also opens a path for new basic research to investigate the importance of TGFBI in the pathophysiology of endometriosis. Further studies are needed to confirm the diagnostic potential of a model based on TGFBI and CA-125 for the non-invasive diagnosis of endometriosis. STUDY FUNDING/COMPETING INTEREST(S): The preparation of this manuscript was supported by grant J3-1755 from the Slovenian Research Agency to T.L.R and EU H2020-MSCA-RISE project TRENDO (grant 101008193). All authors declare that they have no conflicts of interest. TRIAL REGISTRATION NUMBER: NCT0459154.
引用
- Janša V, Pušić Novak M, Ban Frangež H, et al. TGFBI as a candidate biomarker for non-invasive diagnosis of early-stage endometriosis. Hum Reprod. 2023. PMID: 37187159. doi:10.1093/humrep/dead091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。